Section Arrow
ALXO.NASDAQ
- ALX Oncology Holdings
Quotes are at least 15-min delayed:2024/05/13 20:05 EDT
Last
 15.61
-0.6 (-3.70%)
Day High 
16.97 
Prev. Close
16.21 
1-M High
17.825 
Volume 
438.23K 
Bid
15.21
Ask
15.64
Day Low
15.4478 
Open
16.55 
1-M Low
11.8 
Market Cap 
818.59M 
Currency USD 
P/E -- 
%Yield
10-SMA 16.6 
20-SMA 16.02 
50-SMA 13.88 
52-W High 17.825 
52-W Low 3.9357 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.74/-2.38
Enterprise Value
834.21M
Balance Sheet
Book Value Per Share
3.76
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NVAXNovavax13.11+4.23+47.64%-- 
DNAGinkgo Bioworks Holdings0.8407+0.0798+10.49%-- 
ACIUAC Immune SA3.3+0.99+42.86%-- 
JAGXJaguar Health0.290795-0.001305-0.45%-- 
TVGNTevogen Bio Holdings1+0.0155+1.57%-- 
Quotes are at least 15-min delayed:2024/05/13 20:05 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.